Introduction to Patent Law
A patent is a statutory right granted by the government to an inventor for a limited period, in exchange for full disclosure of the invention to the public. This bargain between the inventor and society forms the cornerstone of the patent system - the inventor receives exclusive rights to exploit the invention commercially, while society benefits from the knowledge disclosed.
In India, patents are governed by the Patents Act, 1970 (as amended), which came into force on April 20, 1972. The Act has undergone significant amendments in 1999, 2002, and 2005 to align with India's obligations under the TRIPS Agreement.
The patent system operates on a quid pro quo principle: the inventor discloses the complete details of the invention to the public, enabling others to learn from it. In return, the government grants exclusive rights for a limited period (20 years from filing date). After expiry, the invention enters the public domain.
Definition of Invention - Section 2(1)(j)
This definition establishes three fundamental requirements for an invention to be patentable:
- Newness (Novelty) - The product or process must be new
- Inventive Step - Must involve technical advance or economic significance
- Industrial Application - Must be capable of being made or used in industry
Analysis of Key Terms
1. "New Product or Process"
The term "new" implies novelty - the invention must not have been anticipated by prior publication or prior use anywhere in the world. India follows an absolute novelty standard, meaning the invention must be novel globally, not just within India.
2. Product Patents vs Process Patents
- Product Patent: Protects the product itself, regardless of how it is made. Example: A new pharmaceutical compound.
- Process Patent: Protects the method of making a product. Others can make the same product using a different process. Example: A new manufacturing method for an existing drug.
Before 2005, India only granted process patents for pharmaceuticals and agrochemicals (under the 1970 Act). The 2005 Amendment introduced product patents for these sectors, bringing India into TRIPS compliance. This had significant implications for generic drug manufacturers.
Patentability Criteria: Novelty
Novelty means the invention is not part of the "prior art" - i.e., it has not been made available to the public before the priority date of the patent application through any of the following:
- Prior publication in any document anywhere in the world
- Prior public knowledge or public use in India
- Prior patent applications (published or unpublished) with earlier priority dates
- Prior oral descriptions or demonstrations
Grace Period
Under Section 31, certain disclosures within 12 months before the filing date do not destroy novelty:
- Disclosure at a recognized exhibition
- Disclosure before a learned society
- Disclosure due to wrongful taking from the applicant
The Supreme Court held that to anticipate a patent, the prior publication must contain clear and unmistakable directions to do what the patentee claims to have invented. Mosaic of prior art citations cannot be combined to establish anticipation - each document must be self-contained.
Patentability Criteria: Inventive Step
The inventive step requirement ensures that patents are granted only for genuine innovations, not for trivial modifications. Two key components must be analyzed:
1. Technical Advance or Economic Significance
- Technical Advance: The invention provides a technical improvement over existing solutions - better efficiency, performance, reliability, or a new technical effect.
- Economic Significance: The invention provides commercial value - cost reduction, improved productivity, or market advantage.
2. Non-Obviousness to Person Skilled in the Art (POSITA)
The invention must not be obvious to a hypothetical person having ordinary skill in the relevant technical field. POSITA is presumed to have:
- Knowledge of all relevant prior art
- Ability to undertake routine experimentation
- No inventive capacity
An invention is obvious if a POSITA would have been motivated to try the claimed combination with a reasonable expectation of success. However, if the result was unexpected or surprisingly better than anticipated, this may indicate non-obviousness.
Factors Indicating Non-Obviousness
- Long-felt but unresolved need in the industry
- Commercial success of the invention
- Failure of others to solve the problem
- Skepticism by experts about feasibility
- Teaching away by prior art
Patentability Criteria: Industrial Application
This requirement ensures that patents are granted only for practical, usable inventions - not for abstract theories or speculative ideas. The term "industry" is interpreted broadly to include:
- Manufacturing industries
- Agriculture and horticulture
- Service industries
- Healthcare and medical treatment
What Lacks Industrial Applicability?
- Perpetual motion machines (violate laws of physics)
- Methods of performing mental acts
- Theoretical models without practical application
- Inventions with no disclosed utility
The specification must disclose at least one specific, substantial, and credible utility. Vague or theoretical assertions of utility are insufficient. For pharmaceutical inventions, in vitro data showing biological activity may suffice if it reasonably predicts efficacy.
Patent vs Other Intellectual Property Rights
Understanding how patents differ from other IP rights is crucial for advising clients on the appropriate protection strategy:
| Aspect | Patent | Copyright | Trademark | Trade Secret |
|---|---|---|---|---|
| Subject Matter | Inventions (technical solutions) | Original works of authorship | Brand identifiers | Confidential business information |
| Protection For | Ideas, concepts, methods | Expression, not ideas | Source identification | Valuable secrets |
| Registration | Mandatory | Optional (automatic) | Highly recommended | Not applicable |
| Duration | 20 years from filing | Author's life + 60 years | 10 years, renewable indefinitely | As long as kept secret |
| Disclosure | Full disclosure required | Publication optional | Public use | Secrecy essential |
A single product may be protected by multiple IP rights: patents protect the technology, trademarks protect the brand, design rights protect appearance, and trade secrets protect manufacturing know-how. Effective IP strategy often involves layering these protections.
History of Patent Law in India
Colonial Era
- 1856: First patent legislation - Act VI of 1856 based on British Patent Law of 1852
- 1859: Act XV of 1859 renamed as "Act for granting exclusive privileges to inventors"
- 1872: Patents and Designs Protection Act
- 1883: Protection of Inventions Act
- 1888: Inventions and Designs Act
- 1911: Indian Patents and Designs Act - comprehensive legislation that lasted until 1970
Post-Independence Development
After independence, concerns arose that the 1911 Act favored foreign patent holders and hindered India's industrial development, particularly in pharmaceuticals. Key developments:
- 1949: Patent Enquiry Committee (Tek Chand Committee) recommended reforms
- 1957: Justice Ayyangar Committee Report - comprehensive review recommending major changes
- 1970: Patents Act, 1970 enacted based on Ayyangar Committee recommendations
- 1972: Patents Act came into force on April 20, 1972
The Report recommended: (1) Abolition of product patents for food, medicine, and chemicals - only process patents to be granted; (2) Reduction of patent term; (3) Strengthening compulsory licensing provisions; (4) License of right provisions. These formed the basis of the Patents Act, 1970.
TRIPS-Compliant Amendments
- 1999 Amendment: Introduced mailbox system for pharmaceutical patent applications and Exclusive Marketing Rights (EMR)
- 2002 Amendment: Changed patent term to 20 years, introduced reversal of burden of proof in process patent infringement
- 2005 Amendment: Introduced product patents for pharmaceuticals and agrochemicals, Section 3(d) provisions, pre-grant opposition, compulsory licensing modifications
The Indian patent system balances innovation incentives with public interest concerns, particularly access to medicines. Section 3(d), compulsory licensing provisions (Sections 84-92), and Government use provisions (Section 100) reflect this balance - safeguards absent in most developed country patent laws.